Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185393
Status:
COMPLETED
Last Update Posted:
2008-12-01
First Post:
2005-09-12
Brief Title:
Treatment With 90Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma Stage III or IV Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Efficacy and Safety of Subsequent Treatment With 90Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkins Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy A Prospective Multicenter Randomized Phase III Clinical Trial
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to test 90Y-ibritumomab tiuxetan a radioactive antibody in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy The radioactive antibody will be compared with no further treatment to see which is better in the long term after standard lymphoma treatment
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer Schering Pharma AG Germany
Bayer Schering Pharma AG Germany is the sponsor of the trial
Bayer Schering Pharma AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NHL FIT | None | None | None |
| 304820 | None | None | None |